China Biopharma Inc. Manufacturing Partner Receives SFDA Approval to Deliver Flu Vaccine for the First Batch Release of the 2006-2007 Season.

HANGZHOU, China -- China Biopharma Inc. (OTCBB: TEDG) today announced that Zhejiang Tianyuan Biopharmaceutical, the Company's manufacturing joint venture partner, received approval from the Chinese State Food and Drug Administration (SFDA) to deliver its flu vaccine product for the first batch release of the 2006-2007 influenza season. The Company commenced shipping of the first lots of its flu vaccine product last week to local Centers for Disease Control & Prevention (China CDCs) and hospitals.

"We are very pleased that our flu vaccine is among the first to be delivered and made available to the general public in China this season," said Dr. Jean-Denis Shu, chief executive officer and chief scientist of China Biopharma's China operation. "We believe our flu vaccine will prove beneficial to many this year, and expect that physicians will adopt the China CDCs recent recommendations to begin immunizing against influenza as soon as the vaccine is available."

About China Biopharma Inc.

China Biopharma (formerly Techedge Inc.) is a fast growing developer, producer and distributor of biopharmaceutical products in China. Through its wholly owned subsidiary, China Biopharma Limited, the Company owns the majority interest of Zhejiang Tianyuan Biotech Co., Ltd. The Company's current products consist of human vaccines against influenza, epidemic hemorrhagic fever (HFV), and Japanese Encephalitis (JEV). With its investment and ownership of local Chinese biopharmaceutical companies, the Company plans to build a leading biopharmaceutical company in China by leveraging its manufacturing and marketing capabilities and introducing advanced technologies, best products, and an experienced management team. With a fast growing market, newly completed production facilities, and several other new vaccines in the pipeline, the Company expects to see steady business growth in the near future. For more information, visit its website at www.chinabiopharma.com.cn.

Safe Harbor Statement

Some of the statements made in this press release discuss future events and developments, including the Company's future business strategy and its ability to generate revenue, income and cash flow, and should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements can generally be identified by words such as "expect," "anticipate," "believe," "estimate," "intend," "plan," and similar expressions. These statements involve a high degree of risk and uncertainty that exists in the Company's operations and business environment and are subject to change based on various factors that could cause actual Company results, performance, plans, goals and objectives to differ materially from those contemplated or implied in these forward-looking statements. Actual results may be different from anticipated results for a number of reasons, including the Company's new and uncertain business model, uncertainty regarding acceptance of the Company's products and services and the Company's limited operating history.